RxDoctor Payments Data

Juan Santos, MD

Neurology · Corpus Christi, TXNPI 1376508101

Payments from drug & device makers

$81,172in general payments, 2019–2025

Across 875 payments — averaging $92.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$55K
  • Otter Pharmaceuticals, LLC$4K
  • UCB, Inc.$2K
  • Johnson & Johnson$1K
  • Medtronic$1K
  • Kyowa Kirin, Inc.$1K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$2,7523%
  • Speaking & faculty fees$52,59865%
  • Travel & lodging$2,2773%
  • Food & beverage$23,52229%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$54,925
Otter Pharmaceuticals, LLC14$4,027
UCB, Inc.84$2,420
Johnson & Johnson20$1,280
Medtronic(2 entities)13$1,272
Kyowa Kirin, Inc.45$1,221
Amgen(2 entities)15$1,092
Genentech USA, Inc.46$1,014
Lilly USA, LLC29$891
Neurelis, Inc.24$792
Teva Pharmaceuticals USA, Inc.23$742
SK Life Science, Inc.28$715
AstraZeneca20$675
Novartis38$666
Lundbeck LLC35$662
Sanofi27$631
Eisai Inc.23$613
Otsuka America Pharmaceutical, Inc.8$603
Sunovion Pharmaceuticals Inc.25$487
Biogen24$467
Acadia Pharmaceuticals Inc12$449
Neurocrine Biosciences, Inc.20$446
Bristol Myers Squibb18$439
Acorda Therapeutics, Inc13$389
MDD US Operations, LLC19$378
EMD Serono, Inc.24$318
Argenx US, Inc.9$312
Adamas Pharmaceuticals, Inc.11$244
Biohaven Pharmaceuticals, Inc.10$228
E.r. Squibb & Sons, L.L.C.5$214
Grifols USA, LLC9$210
Averitas Pharma Inc.4$185
Vanda Pharmaceuticals Inc.6$184
Catalyst Pharmaceuticals, Inc.4$172
Corium, LLC6$159
Nevro Corp.3$139
ANI Pharmaceuticals, Inc.3$135
Livanova USA, Inc.5$134
Bayer1$122
Harmony Biosciences LLC1$112
Octapharma USA, Inc.5$100
Melinta Therapeutics, LLC1$91
Pfizer4$90
Esperion Therapeutics, Inc.1$84
Chiesi USA, Inc.1$74
TG Therapeutics, Inc.1$64
CSL Behring3$57
Upsher-smith Laboratories LLC3$56
Biohaven Pharmaceutical Holding Company Ltd.3$47
Aquestive Therapeutics, Inc.3$47
Amneal Pharmaceuticals LLC3$46
Merz Pharmaceuticals, LLC1$38
Jazz Pharmaceuticals Inc.1$31
Zogenix Inc.2$31
Avanir Pharmaceuticals, Inc.2$28
GE HealthCare1$23
Sanofi-aventis U.S. LLC1$23
Takeda Pharmaceuticals U.S.A., Inc.1$22
Aprecia Pharmaceuticals, LLC1$18
Greenwich Biosciences, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,172 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$101,539
Medicare patients
294
Services billed
1,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4696$810,168
PanzygaImmun Glob G(Igg)-Ifas/Glycine26$192,709
XcopriCenobamate89$117,836
NuplazidPimavanserin Tartrate22$106,973
Avonex (4 Pack)Interferon Beta-1a13$104,934
Kesimpta PenOfatumumab11$94,550
MestinonPyridostigmine Bromide11$86,057
BriviactBrivaracetam55$81,474
Droxidopa26$77,359
NourianzIstradefylline21$73,635
BotoxOnabotulinumtoxina50$67,563
Dimethyl Fumarate11$58,927
NayzilamMidazolam20$57,132
RexultiBrexpiprazole33$50,197
UbrelvyUbrogepant32$42,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$210$810,16896 claims
PfizerPanzyga, Nurtec Odt$90$233,35952 claims
AbbVieBotox, Ubrelvy, Qulipta, Namzaric$54,925$183,169169 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$2,420$151,48786 claims
SK Life Science, Inc.Xcopri$715$117,83689 claims
Acadia Pharmaceuticals IncNuplazid$449$106,97322 claims
BiogenAvonex (4 Pack)$467$104,93413 claims
Kyowa Kirin, Inc.Nourianz$1,221$73,63521 claims
Otsuka America Pharmaceutical, Inc.Rexulti$603$50,19733 claims
Eisai Inc.Fycompa$613$25,34921 claims
Sunovion Pharmaceuticals Inc.Aptiom$487$14,05711 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$46$4,04112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →